Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.46 |
| ▸ | CHKA | P35790 | 11/20 | 0.46 |
| ▸ | YTHDC1 | Q96MU7 | 2/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.42 |
| ▸ | CHKB | Q9Y259 | 3/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30332447 | 1.00 | LMNA (0.50) | LMNATP53ADORA2ACHKAYTHDC1 | |
| SCHEMBL30332114 | 0.93 | ADORA2A (0.49) | LMNATP53ADORA2AYTHDC1ADORA3 | |
| SCHEMBL16714635 | 0.93 | ADORA2A (0.49) | LMNATP53ADORA2ACHKAYTHDC1 | |
| SCHEMBL786455 | 0.93 | ADORA2A (0.49) | LMNATP53ADORA2AYTHDC1ADORA3 | |
| SCHEMBL786016 | 0.92 | ADORA2A (0.50) | LMNATP53ADORA2AYTHDC1ADORA3 | |
| SCHEMBL30584024 | 0.92 | ADORA2A (0.50) | LMNATP53ADORA2AYTHDC1ADORA3 | |
| SCHEMBL19553671 | 0.90 | LMNA (0.55) | LMNATP53ADORA2ACHKAADORA3 | |
| SCHEMBL19575552 | 0.90 | LMNA (0.55) | LMNATP53ADORA2ACHKAADORA3 | |
| SCHEMBL11961123 | 0.89 | LMNA (0.48) | LMNATP53ADORA2ACHKAYTHDC1 | |
| SCHEMBL30677364 | 0.89 | LMNA (0.48) | LMNATP53ADORA2ACHKAYTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438068-B1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2017-03-01 | — | — | EP | disclosed |
| US-9023857-B2 | Substituted 6-(2-aminobenzylamino)purine derivatives, their use as medicaments and preparations containing these compounds | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2015-05-05 | — | — | US | disclosed |
| EP-2391626-B1 | SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS | Univerzita Palackého v Olomouci (CZ) | 2014-10-01 | — | — | EP | disclosed |
| US-8492391-B2 | Substituted 6-(2-hydroxybenzylamino)purine derivatives, their use as medicaments and compositions containing these derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2013-07-23 | — | — | US | disclosed |
| EP-2438068-A1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2012-04-11 | — | — | EP | disclosed |
| US-20120070512-A1 | Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2012-03-22 | — | — | US | disclosed |
| EP-2391626-A2 | SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS | Univerzita Palackého v Olomouci (CZ) | 2011-12-07 | — | — | EP | disclosed |
| US-20110287111-A1 | SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2011-11-24 | — | — | US | disclosed |
| WO-2010139289-A1 | SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2010-12-09 | — | — | WO | disclosed |
| WO-2010085924-A2 | SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110287111-A1 | SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS | CDK6, CCNI, CDK2 | LMNA 1802/4885TP53 1013/4885ADORA2A 91/4885 |
| US-20120070512-A1 | Substituted 6-(2-hydroxybenzylamino)purine Derivatives, Their Use as Medicaments and Compositions Containing These Derivatives | CDK6, CCNI, CDK2 | LMNA 1717/4885TP53 1245/4885ADORA2A 95/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.